Robert M Garbaccio

This inventor holds 25 USPTO granted patents and 4 published patent applications and 4 EPO patents, primarily in Drug Delivery Technologies. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Ambrx, Inc.. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert M Garbaccio. Retrieved from https://idiyas.com/inventor/robert-m-garbaccio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 4)

% Patents Active = 44.0

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 57(Granted Patents)

Location History:

Landsdale, PA (US) (2010)
West Point, PA (US) (2015)
Lansdale, PA (US) (2006 - 2024)

Company Filing History:

13 out of 2,405

Merck Sharp + Dohme Corp.

Alnylam Pharmaceuticals, Inc.

Sloan-Kettering Institute for Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

Phosphonate Linkers

Antibody Conjugates

Mitotic Kinesin Inhibitors

Intracellular Delivery

Drug Conjugates

Poly(Amide) Polymers

Checkpoint Kinase Inhibitors

Agonist Activity

Bicyclic Pyrimidinones

Fluorinated Inhibitors

Aminomethyl Derivatives

Macrocycles

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11883500 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2024-01-30),

2. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),

3. 11554172 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2023-01-17),

4. 11510993 - Antibody drug conjugate for anti-inflammatory applications (2022-11-29),

5. 10869929 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2020-12-22),

6. 10800826 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2020-10-13),

7. 10550190 - Phosphate based linkers for intracellular delivery of drug conjugates (2020-02-04),

8. 9139576 - Aminomethyl biaryl benzotriazole derivatives (2015-09-22),

9. 8987377 - Poly(amide) polymers for the delivery of oligonucleotides (2015-03-24),

10. 8975286 - Ether benzotriazole derivatives (2015-03-10),

11. 8785481 - Ether benzotriazole derivatives (2014-07-22),

12. 8329697 - Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors (2012-12-11),

13. 7732472 - Mitotic kinesin inhibitors (2010-06-08),

14. 7723365 - Mitotic kinesin inhibitors (2010-05-25),

15. 7632833 - Mitotic kinesin inhibitors (2009-12-15),

Title: The Innovative Contributions of Robert M. Garbaccio

Introduction

Robert M. Garbaccio, based in Lansdale, Pennsylvania, is a notable inventor with a remarkable portfolio of 25 patents. His work primarily focuses on biopharmaceutical innovations that have substantial implications for treating various metabolic disorders.

Latest Patents

Among his latest contributions are two significant patents:

1. **Phosphonate Linkers** - This patent describes phosphonate linkers and their utility in enhancing the cellular retention of compounds. The innovation highlights the effectiveness of these linkers in facilitating the delivery of compounds with passive cell permeability, thereby improving their therapeutic potential.

2. **Antibody Peptide Conjugates** - Garbaccio's next patent details antibody peptide conjugates (APCs) that exhibit agonist activity at both glucagon and glucagon-like peptide-1 receptors. These conjugates have been modified to resist cleavage by dipeptidyl peptidase IV, enhancing the in vivo half-life of the peptide analog. This innovation aims to provide treatment options for metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Career Highlights

Robert M. Garbaccio has made significant advancements in pharmaceutical research during his career, contributing to major companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His work has paved the way for developing new therapeutic strategies that hold promise for improving patient outcomes in metabolic health.

Collaborations

Throughout his career, Garbaccio has collaborated with prominent figures in the field, including Mark E. Fraley and Jeffrey Curtis Kern. These collaborations have fostered an environment of innovation, leading to breakthroughs with real-world applications.

Conclusion

Robert M. Garbaccio stands out as a distinguished inventor whose contributions, reflected in his numerous patents, have had a substantial impact on the pharmaceutical industry. His continued innovation in the realm of biopharmaceuticals showcases the importance of inventive thinking in addressing complex health challenges.

Profile summary based on public USPTO records.